Who are The Cancer Letter readers?

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

After 45 years of covering oncology, we stopped and asked our readers: who are you?

In a survey sent out to The Cancer Letter’s weekly mailing list, we asked key questions about our readers, their professional degrees, their fields of interest, and their satisfaction with our coverage.

We were pleased to learn that you like us: 83.1% of you rated your satisfaction with our reporting of your areas of interest at a 4 or 5 out of 5, with an average score of 4.1 out of 5 (82%).

We sent the survey to a list of 6,000 readers, and received 419 responses (7%).

story1-1

Of the responses, 37.7% are MDs and 35.6% are PhDs. Within that list, 25 are MD PhDs (6%).

story1-2

*terminal degree

You identified yourselves primarily as clinicians (33.7%), basic scientists (27.2%), and administrators (30.3%)—a surprisingly balanced spread.

story1-3

While this survey didn’t include the thousands of readers at institutions that distribute the PDF internally, we were pleased to learn that you love reading our PDF edition as well as our online content. Redesigned in 2017, our PDF edition has won design awards, and is a primary way many of our readers access The Cancer Letter.

The Cancer Letter has over 200 institutional subscribers.
For login or subscription issues, inquiries about group rates, advertising, or any other administrative questions please contact
katie@cancerletter.com.

story1-4

story1-5

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login